GC Genome Corp.
KKRX:3404509,700.00
KRW
-340.00
(-3.39%)
ISIN
KR7340450006
Return %
Stock
S&P 500
1Y
32.51
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Chang-Seok Gi
- Full Time Employees
- 131
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 107, Ihyeon-ro 30beon-gil Yongin-si GY South Korea 16924
- IPO Date
- Jun 11, 2025
- Website
- gcgenome.com
- Similar Companies
- Business
- GC Genome Corporation specializes in clinical genome analysis and genetic diagnosis services, operating primarily in South Korea. The company offers a broad range of over 300 genetic testing services, focusing on Oncology, Pre&Neonatal, Rare Diseases, and Health Check-ups. Its main products include hereditary cancer tests; tissue and liquid biopsy tests for multi-cancer early detection; SNP genotyping services for genetic health checkups; and personalized treatment suggestions. GC Genome operates a CAP-accredited laboratory and leverages advanced AI technology to develop unique diagnostic platforms such as the ai-CANCERCH liquid biopsy test, which can detect and predict six types of cancers—lung, liver, colorectal, pancreatic, esophageal, and ovarian—from a single blood draw. Founded in 2013 as a subsidiary of GC Biopharma, GC Genome has established significant partnerships with national hospitals, universities, and international entities. The company has recently expanded its global reach through a strategic alliance and exclusive license agreement with MP Group in Thailand to commercialize its Genome Health SNP genotyping service, enabling technology transfer and market expansion in Southeast Asia. Additionally, in 2024, GC Genome showcased new clinical data on its AI-based liquid biopsy platform at the American Society of Clinical Oncology (ASCO) Annual Meeting, underscoring its commitment to innovative cancer detection technologies. The commercial launch of the ai-CANCERCH test and the strategic partnerships mark significant operational growth and technology validation within the last two years. GC Genome targets clinical and diagnostic markets, serving healthcare providers and patients requiring genetic testing for early disease detection and personalized medicine. The company continues to emphasize research and development, focusing on enhancing diagnostic accuracy and expanding test offerings. The headquarters is located in Yongin, South Korea, positioning GC Genome as a leader in the genomics diagnostics field in the Asia-Pacific region. The company is part of the broader GC group, a prominent healthcare organization, and aligns with its parent company's strategic initiatives including technology-driven health solutions. Recent major developments include the launch of an AI-based multi-cancer early detection liquid biopsy test, a strategic licensing and collaboration agreement with MP Group for market advancement in Thailand, and continuous clinical research partnerships, notably with US-based Genece Health Inc. and Korean institutions such as KAIST. In summary, GC Genome Corporation provides comprehensive genetic diagnostic services focused on oncology, pre- and neonatal diseases, and rare diseases, with advanced proprietary AI-based technologies. Its recent strides in expanding international collaborations, launching innovative liquid biopsy products, and presenting cutting-edge clinical data reinforce its position as a growing leader in genomic medicine and precision diagnostics.